Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Lenvatinib Plus Pembrolizumab in Resectable Merkel Cell Carcinoma
NCT04869137Phase 2Active, not recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- May 2021
- Primary completion
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib, pembrolizumab in Merkel cell carcinoma (MCC), sponsored by Moffitt Cancer Center. Started May 2021; status: active, not recruiting.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT04869137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04869137.